Opaganib Downregulates N-Myc Expression and Suppresses In Vitro and In Vivo Growth of Neuroblastoma Cells

• Published in: Cancers 2024-05, Vol.16 (9), p.1779
• Main Authors: Maines, Lynn W, Keller, Staci N, Smith, Ryan A, Schrecengost, Randy S, Smith, Charles D
• Format: Article
• Language: English
• Subjects: Analysis; Antibodies; Antimitotic agents; Antineoplastic agents; Antineoplastic drugs; Antitumor activity; Autophagy; Brain tumors; c-Myc protein; Cancer; Cancer therapies; Care and treatment; Cell culture; Cell proliferation; Chemotherapy; Clinical trials; CTLA-4 protein; Cytotoxicity; Desaturase; Development and progression; Dosage and administration; Drugs; Gene amplification; Growth; Immunocompetence; Infants; Inflammation; Intracellular signalling; Irinotecan; Kinases; Laboratory animals; Lipid metabolism; Lipids; Mcl-1 protein; Medical prognosis; Metabolism; Myc protein; MYCN gene; N-Myc protein; Neuroblastoma; Neuroblasts; Patients; Phosphates; Proteins; Sphingosine; Toxicity; Tumor cells; Tumors; Type 2 diabetes; Viral antibodies; Xenografts
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16091779

Neuroblastoma (NB), the most common cancer in infants and the most common solid tumor outside the brain in children, grows aggressively and responds poorly to current therapies. We have identified a new drug (opaganib, also known as ABC294640) that modulates sphingolipid metabolism by inhibiting the synthesis of sphingosine 1-phosphate (S1P) by sphingosine kinase-2 and elevating dihydroceramides by inhibition of dihydroceramide desaturase. The present studies sought to determine the potential therapeutic activity of opaganib in cell culture and xenograft models of NB. Cytotoxicity assays demonstrated that NB cells, including cells with amplified , are effectively killed by opaganib concentrations well below those that accumulate in tumors in vivo. Opaganib was shown to cause dose-dependent decreases in S1P and hexosylceramide levels in Neuro-2a cells, while concurrently elevating levels of dihydroceramides. As with other tumor cells, opaganib reduced c-Myc and Mcl-1 protein levels in Neuro-2a cells, and also reduced the expression of the N-Myc protein. The in vivo growth of xenografts of human SK-N-(BE)2 cells with amplified was suppressed by oral administration of opaganib at doses that are well tolerated in mice. Combining opaganib with temozolomide plus irinotecan, considered the backbone for therapy of relapsed or refractory NB, resulted in increased antitumor activity in vivo compared with temozolomide plus irinotecan or opaganib alone. Mice did not lose additional weight when opaganib was combined with temozolomide plus irinotecan, indicating that the combination is well tolerated. Opaganib has additive antitumor activity toward Neuro-2a tumors when combined with the checkpoint inhibitor anti-CTLA-4 antibody; however, the combination of opaganib with anti-PD-1 or anti-PD-L1 antibodies did not provide increased antitumor activity over that seen with opaganib alone. Overall, the data demonstrate that opaganib modulates sphingolipid metabolism and intracellular signaling in NB cells and inhibits NB tumor growth alone and in combination with other anticancer drugs. Amplified does not confer resistance to opaganib, and, in fact, the drug attenuates the expression of both c-Myc and N-Myc. The safety of opaganib has been established in clinical trials with adults with advanced cancer or severe COVID-19, and so opaganib has excellent potential for treating patients with NB, particularly in combination with temozolomide and irinotecan or anti-CTLA-4 antibody.